Erbitux significantly extends survival by 7.5 Months in mCRC RAS wild-type patients when compared with Bevacizumab: New analysis of FIRE-3 AIO study

Merck Serono, the biopharmaceutical division of Merck, has announced that the German cooperative investigator group AIO (Arbeitsgemeinschaft Internistische Onkologie) reported new data from the Phase III head-to-head clinical trial FIRE-3, which show a clinically relevant improvement from Erbitux® (cetuximab) plus FOLFIRI versus bevacizumab plus FOLFIRI as 1st line treatment in metastatic colorectal cancer (mCRC) in patients with RAS wild-type tumors.[1] The new data, from a preplanned exploratory analysis, were presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO)...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news